Research & Literature

New and Emerging Treatment Options for Gastroenteropancreatic Neuroendocrine Tumors.

Phan AT, Kunz PL, Reidy-Lagunes DL

Clinical advances in hematology & oncology : H&O 2015; (13(5 Suppl 5)):1-18; quiz 1 p following 18.

Liver-directed surgery of neuroendocrine metastases: What is the optimal strategy?

Maxwell JE, Sherman SK, O'Dorisio TM, et al.

Surgery 2016; (159(1)):320-33.

The Impact of 68Ga-DOTATATE PET/CT Imaging on Management of Patients with Neuroendocrine Tumors: Experience from a National Referral Center in the United Kingdom.

Skoura E, Michopoulou S, Mohmaduvesh M, et al.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2016; (57(1)):34-40 doi:10.2967/jnumed.115.166017.

Safety and Efficacy of 68Ga-DOTATATE PET/CT for Diagnosis, Staging, and Treatment Management of Neuroendocrine Tumors.

Deppen SA, Liu E, Blume JD, et al.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2016; (57(5)):708-14 doi:10.2967/jnumed.115.163865.

Spontaneous hypoglycemia: diagnostic evaluation and management.

Kandaswamy L, Raghavan R, Pappachan JM

Endocrine 2016; (53(1)):47-57 doi:10.1007/s12020-016-0902-0.

Inhibition of Peripheral Synthesis of Serotonin as a New Target in Neuroendocrine Tumors.

Molina-Cerrillo J, Alonso-Gordoa T, Martínez-Sáez O, Grande E

The oncologist 2016; (21(6)):701-7 doi:10.1634/theoncologist.2015-0455.

Aggressive Surgical Approach to the Management of Neuroendocrine Tumors: A Report of 1,000 Surgical Cytoreductions by a Single Institution.

Woltering EA, Voros BA, Beyer DT, et al.

Journal of the American College of Surgeons 2017; (224(4)):434-447 doi:10.1016/j.jamcollsurg.2016.12.032.

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Radiological, Nuclear Medicine & Hybrid Imaging.

Sundin A, Arnold R, Baudin E, et al.

Neuroendocrinology 2017; (105(3)):212-244 doi:10.1159/000471879.

Most of the Intended Management Changes After 68Ga-DOTATATE PET/CT Are Implemented.

Calais J, Czernin J, Eiber M, et al.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2017; (58(11)):1793-1796 doi:10.2967/jnumed.117.192450.

Somatostatin Receptor 2-Targeting Compounds.

Smit Duijzentkunst DA, Kwekkeboom DJ, Bodei L

Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2017; (58(Suppl 2)):54S-60S doi:10.2967/jnumed.117.191015.

A 17-year-old male with a Small Bowel Neuroendocrine Tumor: flushing differential diagnosis.

Forero Molina MA, Garcia E, Gonzalez-Devia D, et al.

The World Allergy Organization journal 2017; (10(1)):30 doi:10.1186/s40413-017-0161-4.

The role of multimodal treatment in patients with advanced lung neuroendocrine tumors.

Fazio N, Ungaro A, Spada F, et al.

Journal of thoracic disease 2017; (9(Suppl 15)):S1501-S1510 doi:10.21037/jtd.2017.06.14.

Telotristat Ethyl for Patients With Carcinoid Syndrome Associated With Chest Pain and Hypertension.

Kasi PM

Pancreas 2018; (47(1)):e2 doi:10.1097/MPA.0000000000000971.

Telotristat ethyl: a novel agent for the therapy of carcinoid syndrome diarrhea.

Dillon JS, Chandrasekharan C

Future oncology (London, England) 2018; (14(12)):1155-1164 doi:10.2217/fon-2017-0340.

Telotristat Ethyl: A Review in Carcinoid Syndrome Diarrhoea.

Lyseng-Williamson KA

Drugs 2018; (78(9)):941-950 doi:10.1007/s40265-018-0935-1.

BIOCHEMICAL RESPONSES IN SYMPTOMATIC AND ASYMPTOMATIC PATIENTS WITH NEUROENDOCRINE TUMORS: POOLED ANALYSIS OF 2 PHASE 3 TRIALS.

Mirakhur B, Pavel ME, Pommier RF, et al.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2018; doi:10.4158/EP-2018-0296.

Effective cytoreduction can be achieved in patients with numerous neuroendocrine tumor liver metastases (NETLMs).

Scott AT, Breheny PJ, Keck KJ, et al.

Surgery 2019; (165(1)):166-175 doi:10.1016/j.surg.2018.04.070.

Effect of Lanreotide Depot/Autogel on Urinary 5-Hydroxyindoleacetic Acid and Plasma Chromogranin A Biomarkers in Nonfunctional Metastatic Enteropancreatic Neuroendocrine Tumors.

Pavel ME, Phan AT, Wolin EM, et al.

The oncologist 2019; (24(4)):463-474 doi:10.1634/theoncologist.2018-0217.

Aspects regarding nomenclature, classification and pathology of neuroendocrine neoplasms of the digestive system - a review.

Păun I, Becheanu G, Costin AI, et al.

Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie 2018; (59(3)):673-678.

What Is New in the 2017 World Health Organization Classification and 8th American Joint Committee on Cancer Staging System for Pancreatic Neuroendocrine Neoplasms?

Choe J, Kim KW, Kim HJ, et al.

Korean journal of radiology 2019; (20(1)):5-17 doi:10.3348/kjr.2018.0040.

Nutritional and vitamin status in patients with neuroendocrine neoplasms.

Clement DS, Tesselaar ME, van Leerdam ME, et al.

World journal of gastroenterology 2019; (25(10)):1171-1184 doi:10.3748/wjg.v25.i10.1171.

Insulinoma-associated protein 1 expression in primary and metastatic neuroendocrine neoplasms of the gastrointestinal and pancreaticobiliary tracts.

González I, Lu HC, Sninsky J, et al.

Histopathology 2019; (75(4)):568-577 doi:10.1111/his.13899.

Measurement of urinary 5-HIAA: correlation between spot versus 24-h urine collection.

Calanchini M, Tadman M, Krogh J, et al.

Endocrine connections 2019; (8(8)):1082-1088.

Gastroenteropancreatic High-Grade Neuroendocrine Neoplasms: Histology and Molecular Analysis, Two Sides of the Same Coin.

Busico A, Maisonneuve P, Prinzi N, et al.

Neuroendocrinology 2020; (110(7-8)):616-629 doi:10.1159/000503722.

Challenges with Validating Nonharmonized Assays.

Hackenmueller SA

The journal of applied laboratory medicine 2019; (4(1)):1-3 doi:10.1373/jalm.2019.029272.

Impact of initial imaging with gallium-68 dotatate PET/CT on diagnosis and management of patients with neuroendocrine tumors.

Crown A, Rocha FG, Raghu P, et al.

Journal of surgical oncology 2020; (121(3)):480-485 doi:10.1002/jso.25812.

Treatment Patterns and Health Resource Use Among Patients with Metastatic Gastroenteropancreatic Neuroendocrine Tumors Treated at a Tertiary Referral Center.

Jalbert JJ, Casciano R, Meng J, et al.

The oncologist 2020; (25(4)):e644-e650 doi:10.1634/theoncologist.2019-0691.

68Ga-DOTATATE PET/CT Compared with 131I-MIBG SPECT/CT in the Evaluation of Neural Crest Tumors.

Shahrokhi P, Emami-Ardekani A, Harsini S, et al.

Asia Oceania journal of nuclear medicine & biology 2020; (8(1)):8-17 doi:10.22038/aojnmb.2019.41343.1280.

Carcinoid Syndrome: A Review.

Gade AK, Olariu E, Douthit NT

Cureus 2020; (12(3)):e7186 doi:10.7759/cureus.7186.

Etoposide and cisplatin versus irinotecan and cisplatin as the first-line therapy for patients with advanced, poorly differentiated gastroenteropancreatic neuroendocrine carcinoma: A randomized phase 2 study.

Zhang P, Li J, Li J, et al.

Cancer 2020; (126 Suppl 9()):2086-2092 doi:10.1002/cncr.32750.

[Gastroenteropancreatic neuroendocrine neoplasms-Heterogeneity, management and perspectives of treatment and research].

Luley K, Gebauer J, Gebauer N, et al.

Der Internist 2020; (61(8)):875-890 doi:10.1007/s00108-020-00832-x.

Randomised phase II trial of CAPTEM or FOLFIRI as SEcond-line therapy in NEuroendocrine CArcinomas and exploratory analysis of predictive role of PET/CT imaging and biological markers (SENECA trial): a study protocol.

Bongiovanni A, Liverani C, Pusceddu S, et al.

BMJ open 2020; (10(7)):e034393 doi:10.1136/bmjopen-2019-034393.

Differential diagnosis of diarrhoea in patients with neuroendocrine tumours: A systematic review.

Khan MS, Walter T, Buchanan-Hughes A, et al.

World journal of gastroenterology 2020; (26(30)):4537-4556 doi:10.3748/wjg.v26.i30.4537.

Patient reported experience of the burden of neuroendocrine tumors and impact of eSHINE Patient Support Program on patient quality of life.

Wakelin K

Asia-Pacific journal of clinical oncology 2020; (16 Suppl 7()):3-8 doi:10.1111/ajco.13477.

Frequency and Causes of False-Positive Elevated Plasma Concentrations of Fasting Gut Hormones in a Specialist Neuroendocrine Tumor Center.

Butler OL, Mekhael MM, Ahmed A, et al.

Frontiers in endocrinology 2020; (11()):606264 doi:10.3389/fendo.2020.606264.

Neuroendocrine Carcinomas of the Canine Mammary Gland: Histopathological and Immunohistochemical Characteristics.

Nakagaki KYR, Nunes MM, Garcia APV, et al.

Frontiers in veterinary science 2020; (7()):621714 doi:10.3389/fvets.2020.621714.

The State of Peptide Receptor Radionuclide Therapy and Its Sequencing among Current Therapeutic Options for Gastroenteropancreatic Neuroendocrine Tumors.

Raymond LM, Korzun T, Kardosh A, et al.

Neuroendocrinology 2021; (111(11)):1086-1098 doi:10.1159/000516015.

Challenges in High-grade Neuroendocrine Neoplasms and Mixed Neuroendocrine/Non-neuroendocrine Neoplasms.

La Rosa S

Endocrine pathology 2021; (32(2)):245-257 doi:10.1007/s12022-021-09676-z.

Tumour grade and primary site predict patterns of recurrence and survival in patients with resected gastroenteropancreatic neuroendocrine tumors.

Watanabe A, Yip L, Hamilton TD, et al.

American journal of surgery 2021; (221(6)):1141-1149 doi:10.1016/j.amjsurg.2021.03.027.

Association between somatostatin analogues and diabetes mellitus in gastroenteropancreatic neuroendocrine tumor patients: A Surveillance, Epidemiology, and End Results-Medicare analysis of 5235 patients.

Ni K, Yang JY, Baeg K, et al.

Cancer reports (Hoboken, N.J.) 2021; (4(5)):e1387 doi:10.1002/cnr2.1387.

Clinical Utility of 18F-FDG PET in Neuroendocrine Tumors Prior to Peptide Receptor Radionuclide Therapy: A Systematic Review and Meta-Analysis.

Alevroudis E, Spei ME, Chatziioannou SN, et al.

Cancers 2021; (13(8)) doi:10.3390/cancers13081813.

Better Management for Neuroendocrine Neoplasms: A Complex Task Ahead.

Coriat R

Journal of clinical medicine 2021; (10(9)) doi:10.3390/jcm10091859.

Long-Term Treatment with Telotristat Ethyl in Patients with Carcinoid Syndrome Symptoms: Results from the TELEPATH Study.

Hörsch D, Anthony L, Gross DJ, et al.

Neuroendocrinology 2022; (112(3)):298-310 doi:10.1159/000516958.

Bile Acid Malabsorption in Patients with Neuroendocrine Tumors.

Khanna L, Halfdanarson TR, Sonbol MB, et al.

Digestive diseases and sciences 2022; (67(6)):2517-2525 doi:10.1007/s10620-021-07189-7.

An analysis of 130 neuroendocrine tumors G3 regarding prevalence, origin, metastasis, and diagnostic features.

Kasajima A, Konukiewitz B, Schlitter AM, et al.

Virchows Archiv : an international journal of pathology 2022; (480(2)):359-368 doi:10.1007/s00428-021-03202-6.

Vitamin D deficiency and tumor aggressiveness in gastroenteropancreatic neuroendocrine tumors.

Altieri B, Barrea L, Modica R, et al.

Endocrine 2022; (75(2)):623-634 doi:10.1007/s12020-021-02869-w.

Perspectives on the diagnostic, predictive and prognostic markers of neuroendocrine neoplasms (Review).

Ciobanu OA, Martin S, Fica S

Experimental and therapeutic medicine 2021; (22(6)):1479 doi:10.3892/etm.2021.10914.

Emerging Therapeutic Concepts and Latest Diagnostic Advancements Regarding Neuroendocrine Tumors of the Gynecologic Tract.

Georgescu TA, Bohiltea RE, Munteanu O, et al.

Medicina (Kaunas, Lithuania) 2021; (57(12)) doi:10.3390/medicina57121338.

How to Select Patients Affected by Neuroendocrine Neoplasms for Surgery.

Fermi F, Andreasi V, Muffatti F, et al.

Current oncology reports 2022; (24(2)):227-239 doi:10.1007/s11912-022-01200-8.

Radiolabeled Somatostatin Analogues for Diagnosis and Treatment of Neuroendocrine Tumors.

Ambrosini V, Zanoni L, Filice A, et al.

Cancers 2022; (14(4)) doi:10.3390/cancers14041055.

ENETS standardized (synoptic) reporting for endoscopy in neuroendocrine tumors.

Borbath I, Pape UF, Deprez PH, et al.

Journal of neuroendocrinology 2022; (34(3)):e13105 doi:10.1111/jne.13105.

Awareness of drug laboratory test interactions is important for prevention of unnecessary additional diagnostics: An example.

van Balveren JA, Erdem-Eraslan L, Verboeket-van de Venne WPHG, et al.

Clinica chimica acta; international journal of clinical chemistry 2022; (530()):99-103 doi:10.1016/j.cca.2022.03.013.

Neuroendocrine Neoplasms of the Gynecologic Tract.

Virarkar M, Vulasala SS, Morani AC, et al.

Cancers 2022; (14(7)) doi:10.3390/cancers14071835.

A Rare Case of Insulinoma in a Thin, Lean Adult Male: A Case Report.

Khan Md AR, Wazir MH, Waqar S, et al.

Cureus 2022; (14(3)):e23414 doi:10.7759/cureus.23414.

Neuroendocrine Tumors and Peptide Receptor Radionuclide Therapy: When Is the Right Time?

Hope TA, Pavel M, Bergsland EK

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2022; (40(24)):2818-2829 doi:10.1200/JCO.22.00176.

Updates on Diagnostic and Therapeutic Management of Gastrointestinal and Pancreatic NET.

Krug S, Schrader J, Rinke A

Cancers 2022; (14(11)) doi:10.3390/cancers14112628.

Evaluation of multidisciplinary team decisions in neuroendocrine neoplasms: Impact of expert centres.

Zandee WT, Merola E, Poczkaj K, et al.

European journal of cancer care 2022; (31(6)):e13639 doi:10.1111/ecc.13639.

Hedinger Syndrome: A Rare Cardiac Manifestation of Carcinoid Syndrome.

Ghukasyan H

Cureus 2022; (14(7)):e26528 doi:10.7759/cureus.26528.

Preliminary experience with a new institutional tumor board dedicated to patients with neuroendocrine neoplasms.

Trikalinos NA, Hammill C, Liu J, et al.

Abdominal radiology (New York) 2022; (47(12)):4096-4102 doi:10.1007/s00261-022-03707-x.

Well-Differentiated Grade 3 Neuroendocrine Tumors: Characteristics, Treatments, and Outcomes From a Population-Based Study.

Boutin M, Mathews A, Badesha J, et al.

Pancreas 2022; (51(7)):756-762 doi:10.1097/MPA.0000000000002100.

Gastroenteropancreatic Neuroendocrine Tumor Diagnosis: DOTATATE PET/CT.

Kandathil A, Subramaniam RM

PET clinics 2023; (18(2)):189-200 doi:10.1016/j.cpet.2022.11.001.

Bevacizumab plus FOLFIRI after failure of platinum-etoposide first-line chemotherapy in patients with advanced neuroendocrine carcinoma (PRODIGE 41-BEVANEC): a randomised, multicentre, non-comparative, open-label, phase 2 trial.

Walter T, Lievre A, Coriat R, et al.

The Lancet. Oncology 2023; (24(3)):297-306 doi:10.1016/S1470-2045(23)00001-3.

What have we learnt from the past - would treatment decisions for GEP-NET patients differ between 2012 to 2016 by the new recommendations in 2022?

Stiefel R, Lehmann K, Winder T, Siebenhüner AR

BMC cancer 2023; (23(1)):148 doi:10.1186/s12885-023-10567-1.

Neuroendocrine Neoplasms: Genetics and Epigenetics.

Smith J, Barnett E, Rodger EJ, et al.

PET clinics 2023; (18(2)):169-187 doi:10.1016/j.cpet.2022.11.003.

Future therapeutic strategies in the treatment of extrapulmonary neuroendocrine carcinoma: a review.

Robinson MD, Livesey D, Hubner RA, et al.

Therapeutic advances in medical oncology 2023; (15()):17588359231156870 doi:10.1177/17588359231156870.

The role of serotonin inhibition within the treatment of carcinoid syndrome.

George J, Ramage J, White B, Srirajaskanthan R

Endocrine oncology (Bristol, England) 2023; (3(1)):e220077 doi:10.1530/EO-22-0077.

A Comprehensive Review on Neuroendocrine Neoplasms: Presentation, Pathophysiology and Management.

Sultana Q, Kar J, Verma A, et al.

Journal of clinical medicine 2023; (12(15)) doi:10.3390/jcm12155138.

A case of carcinoid syndrome probably exacerbated by hemodialysis in which prochlorperazine maleate was effective.

Oda K, Murata T, Tsujimoto K, et al.

CEN case reports 2024; (13(2)):135-140 doi:10.1007/s13730-023-00814-6.

The assessment of Ki-67 for prognosis of gastroenteropancreatic neuroendocrine neoplasm patients: a systematic review and meta-analysis.

Tao Z, Xue R, Wei Z, et al.

Translational cancer research 2023; (12(8)):1980-1991 doi:10.21037/tcr-23-248.

Epidemiologic trends of and factors associated with overall survival in patients with neuroendocrine tumors over the last two decades in the USA.

Wu P, He D, Chang H, Zhang X

Endocrine connections 2023; (12(12)).

Approach to the Patient: Insulinoma.

Hofland J, Refardt JC, Feelders RA, et al.

The Journal of clinical endocrinology and metabolism 2024; (109(4)):1109-1118 doi:10.1210/clinem/dgad641.

Advances in Endoscopic Diagnosis and Treatment of Gastric Neuroendocrine Neoplasms.

Guo X, Zhao X, Huang G, Yu Y

Digestive diseases and sciences 2024; (69(1)):27-35 doi:10.1007/s10620-023-08180-0.

Treatment modalities favoring outcome in well-differentiated neuroendocrine tumors G3.

Hinterleitner M, Pfeiffer R, Trautwein NF, et al.

Frontiers in endocrinology 2023; (14()):1285529 doi:10.3389/fendo.2023.1285529.

Multimodal management of foregut neuroendocrine neoplasms.

Zhou Y, Li JW, Uedo N

Best practice & research. Clinical gastroenterology 2024; (68()):101889 doi:10.1016/j.bpg.2024.101889.

Digital image analysis of Ki67 hotspot detection and index counting in gastroenteropancreatic neuroendocrine neoplasms.

Saetiew K, Angkathunyakul N, Hunnangkul S, Pongpaibul A

Annals of diagnostic pathology 2024; (71()):152295 doi:10.1016/j.anndiagpath.2024.152295.

Histopathological Features Predicting Neuroendocrine Morphology in Primary Breast Tumors: A Retrospective Analysis.

Ozsen M, Senol K, Tolunay S, et al.

European journal of breast health 2024; (20(2)):110-116 doi:10.4274/ejbh.galenos.2024.2023-12-10.

Critical updates in neuroendocrine tumors: Version 9 American Joint Committee on Cancer staging system for gastroenteropancreatic neuroendocrine tumors.

Chauhan A, Chan K, Halfdanarson TR, et al.

CA: a cancer journal for clinicians 2024; (74(4)):359-367 doi:10.3322/caac.21840.

Value of Surgical Cytoreduction in Patients with Small Intestinal Neuroendocrine Tumors Metastatic to the Liver and Peritoneum.

Gudmundsdottir H, Fogliati A, Grotz TE, et al.

Annals of surgical oncology 2024; (31(8)):5370-5376 doi:10.1245/s10434-024-15316-7.

Neuroendocrine Tumors: Diagnostics.

Sakellis C, Jacene HA

PET clinics 2024; (19(3)):325-339 doi:10.1016/j.cpet.2024.03.008.

Head-to-head: Should Ki67 proliferation index be included in the formal classification of pulmonary neuroendocrine neoplasms?

Pelosi G, Travis WD

Histopathology 2024; (85(4)):535-548 doi:10.1111/his.15206.

Prediction of the First-Pass Metabolism of a Drug After Oral Intake Based on Structural Parameters and Physicochemical Properties.

Hosseini MAH, Alizadeh AA, Shayanfar A

European journal of drug metabolism and pharmacokinetics 2024; (49(4)):449-465 doi:10.1007/s13318-024-00892-6.

[177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study.

Singh S, Halperin D, Myrehaug S, et al.

Lancet (London, England) 2024; (403(10446)):2807-2817 doi:10.1016/S0140-6736(24)00701-3.

Unmasking Carcinoid Syndrome in a Chronic Obstructive Pulmonary Disease (COPD) Patient: A Rare Presentation with Wheezing and Angioedema.

Aleksanyan M, Chadalawada S, Hakobyan K, et al.

Cureus 2024; (16(5)):e61321 doi:10.7759/cureus.61321.

Sex Differences in the Survival of Patients with Neuroendocrine Neoplasms: A Comparative Study of Two National Databases.

Mortagy M, El Asmar ML, Chandrakumaran K, Ramage J

Cancers 2024; (16(13)) doi:10.3390/cancers16132376.

Insulinoma-associated protein-1 (INSM-1) is a useful diagnostic marker for the evaluation of primary thymic neuroendocrine neoplasms: an immunohistochemical study of 27 cases.

Suster D, Chacko D, VanderLaan P, et al.

Virchows Archiv : an international journal of pathology 2025; (486(4)):721-727 doi:10.1007/s00428-024-03904-7.

The University of Iowa Neuroendocrine Tumor Clinic.

Howe JR, Menda Y, Chandrasekharan C, et al.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2025; (31(1)):4-18 doi:10.1016/j.eprac.2024.09.018.

Carcinoid heart disease in patients with advanced small-intestinal neuroendocrine tumors and carcinoid syndrome: a retrospective experience from two European referral centers.

Algeri L, Falkman L, Spada F, et al.

ESMO open 2024; (9(11)):103959 doi:10.1016/j.esmoop.2024.103959.

Circulating Chromogranin A as a Surveillance Biomarker in Patients with Carcinoids-The CASPAR Study.

Meng QH, Halfdanarson TR, Bornhorst JA, et al.

Clinical cancer research : an official journal of the American Association for Cancer Research 2024; (30(24)):5559-5567 doi:10.1158/1078-0432.CCR-24-1875.

Exploring Carcinoid Syndrome in Neuroendocrine Tumors: Insights from a Multidisciplinary Narrative Review.

Marasco M, Romano E, Arrivi G, et al.

Cancers 2024; (16(22)) doi:10.3390/cancers16223831.

Preclinical safety and effectiveness of a long-acting somatostatin analogue [225Ac]Ac-EBTATE against small cell lung cancer and pancreatic neuroendocrine tumors.

Njotu FN, Pougoue Ketchemen J, Babeker H, et al.

European journal of nuclear medicine and molecular imaging 2025; (52(4)):1305-1320 doi:10.1007/s00259-024-07011-2.

Nutritional status and gastroenteropancreatic neuroendocrine neoplasms: lights and shadows with a clinical guide from the NIKE Group.

Vitale G, Gaudenzi G, Oldani M, et al.

Reviews in endocrine & metabolic disorders 2025; (26(2)):161-174 doi:10.1007/s11154-024-09937-2.

Diagnostic relevance of p53 and Rb status in neuroendocrine tumors G3 from different organs: an immunohistochemical study of 465 high-grade neuroendocrine neoplasms.

Kanaan C, Bani MA, Ducreux M, et al.

Virchows Archiv : an international journal of pathology 2025; (486(5)):941-950 doi:10.1007/s00428-024-04006-0.

Epidemiology, treatment and outcomes of gastroenteropancreatic neuroendocrine neoplasms.

Uhlig J, Nie J, Gibson J, et al.

Scientific reports 2024; (14(1)):30536 doi:10.1038/s41598-024-81518-4.

Management of high-grade neuroendocrine neoplasms: impact of functional imaging.

Islam O, Sarti K, Verbruggen L, et al.

Endocrine-related cancer 2025; (32(4)).

Factors Influencing Costs of Cancer Care for Patients with Neuroendocrine Neoplasms.

Weickert MO

Neuroendocrinology 2025; (115(12)):935-956 doi:10.1159/000544050.

Surgical Management of Gastroenteropancreatic Neuroendocrine Tumors.

Kenney LM, Hughes M

Cancers 2025; (17(3)) doi:10.3390/cancers17030377.

Patterns and outcomes of current antitumor therapy for high-grade neuroendocrine neoplasms: perspective of a tertiary referral center.

Melhorn P, Spitzer J, Adel T, et al.

Journal of cancer research and clinical oncology 2025; (151(2)):86 doi:10.1007/s00432-025-06126-9.

Impact of multikinase inhibitors in reshaping the treatment of advanced gastroenteropancreatic neuroendocrine tumors.

Siebenhüner AR, Refardt J, Nicolas GP, et al.

Endocrine-related cancer 2025; (32(6)).

Cost-Effectiveness of [177Lu]Lu-DOTATATE for the Treatment of Newly Diagnosed Advanced Gastroenteropancreatic Neuroendocrine Tumors: An Analysis Based on Results of the NETTER-2 Trial.

Holzgreve A, Unterrainer LM, Tiling M, et al.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2025; (66(7)):1075-1081 doi:10.2967/jnumed.124.269416.

Epidemiology of Neuroendocrine Neoplasms in the US.

Dasari A, Wallace K, Halperin DM, et al.

JAMA network open 2025; (8(6)):e2515798 doi:10.1001/jamanetworkopen.2025.15798.

Advances in Molecular Imaging for Neuroendocrine Neoplasms.

Girod B, Prasad V

Cancers 2025; (17(12)) doi:10.3390/cancers17122013.

Neuroendocrine tumors of the appendix: a comprehensive review of the literature and case presentation.

Vasile L, Barbu LA, Mogoş GFR, et al.

Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie 2025; (66(2)):269-278 doi:10.47162/RJME.66.2.01.

Carcinoid syndrome mimicking irritable bowel syndrome: don't fall into the trap.

Massironi S, Gallo C, Franchina M, et al.

Expert review of gastroenterology & hepatology 2025; (19(10)):1119-1132 doi:10.1080/17474124.2025.2557245.

Gastroenteropancreatic neuroendocrine neoplasms: Clinical-pathologic analysis of 48 cases treated at the Hospital Ángeles del Pedregal in Mexico City between 2018 and 2024.

Sánchez-Arreguín R, Ahumada-Ayala M, Santibañez-Silva V, et al.

Revista de gastroenterologia de Mexico (English) 2025; (90(4)):520-529 doi:10.1016/j.rgmxen.2025.10.014.

Differentiating well-differentiated neuroendocrine tumors grade 3 from poorly differentiated neuroendocrine carcinomas and adenocarcinoma with neuroendocrine differentiation: a comprehensive review.

Bahceci D, Adsay V, Basturk O

Virchows Archiv : an international journal of pathology 2026; (488(1)):45-64 doi:10.1007/s00428-025-04336-7.